Neogen Corporation (NEOG) - Stock Analysis
Last updated: Mar 14, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Neogen shows improving operational execution with a stable revenue base, cost savings initiatives, and positive industry tailwinds. The stock exhibits positive technical momentum and analyst upgrades. Legal headwinds remain but ongoing margin expansion and upcoming earnings confer cautious near-term upside potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong cash generation ⢠Large intangible risk ⢠Negative profitability NEOG shows solid liquidity and near-term cash generation but is weighed down by huge cumulative losses, oversized intangibles and noncash impairments that distort profitability and multiples.
Price Behavior
Key Price Behavior Insights: ⢠Short-term downtrend ⢠Near-term support ⢠Resistance band Support Level: $9.0â$9.8 Resistance Level: $11.2â$11.33 NEOG is in a short-term downtrend, trading at $9.09âabout 14% below its last-month 10.58 SMA and down nearly 20% from $11.33 on Feb 20, with near-term support around $9.0â$9.8 and key resistance at $11.2â$11.33.
Sentiment & News
Key News Insights: ⢠Genomics divestiture ⢠Mixed analyst view ⢠Institutional stake trim Neogen is narrowing its focus by selling its genomics unit to Zoetis for $160M while facing mixed analyst sentiment and a notable institutional stake reduction.
AI Summary
NEOG is now a turnaround bet: if management completes the PetriFilm production transfer cleanly and delivers the announced ~$20M of cost savings to convert strong ~47% gross margins into sustainable free cash flow and netâdebt reduction, the stock can reârate; failure to do so (more writeâoffs, recalls, or distributor breakdowns) will keep impairment risk and leverage constraining value.
Description
Neogen Corporation develops, manufactures and sells products used to detect, mitigate and monitor biological, chemical and sanitary hazards across the food and animal sectors. Its Food Safety business supplies diagnostic test kits and sanitation assays to food and feed producers, processors, grain handlers, dairies, laboratories and related manufacturers to identify pathogens, toxins, residues, allergens and other contaminants, while its Animal Safety business provides veterinary medicines, vaccines, diagnostic tools, disinfectants and genomics services, including drug-residue and toxicology testing for animals. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 1 | Jan 8 | NEOG | Neogen Corporation | Neogen shows improving operational execution with a stable revenue base, cost savings initiatives, and positive industry tailwinds. The stock exhibits positive technical momentum and analyst upgrades. Legal headwinds remain but ongoing margin expansion and upcoming earnings confer cautious near-term upside potential. | Closed | +38.9% |